Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer

OncoImmunology

Volumn 1, Issue 3, 2012, Pages 326-333

  Pere, Helene ^a,b   Tanchot, Corinne ^a   Bayry, Jagadeesh ^c   Terme, Magali ^a   Taieb, Julien ^a   Badoual, Cecile ^a,b   Adotevi, Olivier ^d   Merillon, Nathalie ^a   Marcheteau, Elie ^a   Quillien, Véronique ^e   Banissi, Claire ^f   Carpentier, Alain ^f   Sandoval, Federico ^a   Nizard, Mevyn ^a   Quintin Colonna, Françoise ^a,g   Kroemer, Guido ^b,c,f,h,i   Fridman, Wolf H ^b,c   Zitvogel, Laurence ^i,j   Oudard, Stéphane ^a,b   Tartour, Eric ^a,b  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^e CENTRE EUGÈNE MARQUIS   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^h Institut Gustave Roussy   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j Center of Clinical Investigations CBT507   (France)

more..

Author keywords

Antiangiogenic molecule; CCR4; Chemokine; Regulatory T cell

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ANGIOGENESIS INHIBITOR; BASILIXIMAB; CANCER VACCINE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACLIZUMAB; DENILEUKIN DIFTITOX; IMATINIB; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 35; MACROPHAGE DERIVED CHEMOKINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GITR; MONOCLONAL ANTIBODY OX40; PACLITAXEL; PROTEIN P60; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TOLL LIKE RECEPTOR 8; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CYTOLYSIS; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; FIBROSARCOMA; GASTROINTESTINAL SARCOMA; HUMAN; IMMUNOLOGICAL TOLERANCE; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE FUNCTION; LYMPHOCYTE HOMING; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MELANOMA; METASTATIC MELANOMA; MIGRATION INHIBITION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SARCOMA; T CELL DEPLETION; TUMOR MICROENVIRONMENT;

EID: 84871719877     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.18852     Document Type: Article

References (80)

1. Gershon RK, Gery I, Waksman BH. Suppressive effects of in vivo immunization on PHA responses in vitro. J Immunol 1974; 112:215-21
2. Kojima A, Tanaka-Kojima Y, Sakakura T, Nishizuka Y. Spontaneous development of autoimmune thyroiditis in neonatally thymectomized mice. Lab Invest 1976; 34:550-7
3. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490-500; http://dx.doi.org/10.1038/nri2785
4. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64
5. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-61; http://dx.doi.org/10.1126/science.1079490
6. Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 2003; 112:1437-43
7. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J ExpMed 2006; 203:1701-11; PMID:16818678; http://dx.doi.org/10.1084/jem.20060772
8. de Vries IJ, Castelli C, Huygens C, Jacobs JF, Stockis J, Schuler-Thurner B, et al. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Tregdepleting agents. Clin Cancer Res 2011; 17:841-8; http://dx.doi.org/10.1158/1078-0432.CCR-10-2227
9. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8:523-32; http://dx.doi.org/10.1038/nri2343
10. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001; 194:847-54; http://dx.doi.org/10.1084/jem.194.6.847
11. Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005; 202:919-29; http://dx.doi.org/10.1084/jem.20050463
12. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27:485-517; http://dx.doi.org/10.1146/annurev.immunol.021908.132710
13. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204:1257-65; http://dx.doi.org/10.1084/jem.20062512
14. Boissonnas A, Scholer-Dahirel A, Simon-Blancal V, Pace L, Valet F, Kissenpfennig A, et al. Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity 2010; 32: 266-78; http://dx.doi.org/10.1016/j.immuni.2009.11.015
15. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007; 8:1353-62; http://dx.doi.org/10.1038/ni1536
16. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322:271-5; http://dx.doi.org/10.1126/science.1160062
17. Lehe C, Ghebeh H, Al-Sulaiman A, Al Qudaihi G, Al-Hussein K, Almohareb F, et al. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy. Cancer Res 2008; 68:6350-9; http://dx.doi.org/10.1158/0008-5472.CAN-08-0050
18. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006; 107:628-36; http://dx.doi.org/10.1182/blood-2005-07-2737
19. Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 2008; 31: 101-12; http://dx.doi.org/10.1097/CJI.0b013e318159f5ba
20. Nishikawa H, Jager E, Ritter G, Old LJ, Gnjatic S. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 2005; 106:1008-11; http://dx.doi.org/10.1182/blood-2005-02-0607
21. Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, et al. A CCR4 antagonist combined with vaccines induce antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011; 118:4853-62; http://dx.doi.org/10.1182/blood-2011-01-329656
22. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; http://dx.doi.org/10.1038/nm1093
23. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009; 69:2000-9; http://dx.doi.org/10.1158/0008-5472.CAN-08-2360
24. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475:226-30; http://dx.doi.org/10.1038/nature10169
25. Badoual C, Hans S, Fridman WH, Brasnu D, Erdman S, Tartour E. Revisiting the prognostic value of regulatory T cells in patients with cancer. J Clin Oncol2009; 27:e5-6.
26. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G. Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates. Cancer Res 2011; 71:5601-5; http://dx.doi.org/10.1158/0008-5472.CAN-11-1316
27. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, et al. Prognostic value of tumorinfiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006; 12:465-72; http://dx.doi.org/10.1158/1078-0432.CCR-05-1886
28. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27:186-92; http://dx.doi.org/10.1200/JCO.2008.18.7229
29. Badoual C, Bouchaud G, Agueznay Nel H, Mortier E, Hans S, Gey A, et al. The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 2008; 68:3907-14; http://dx.doi.org/10.1158/0008-5472.CAN-07-6842
30. Badoual C, Sandoval F, Pere H, Hans S, Gey A, Merillon N, et al. Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck 2010; 32:946-58
31. Tartour E, Mathiot C, Fridman WH. Current status of interleukin-2 therapy in cancer. Biomed Pharmacother 1992; 46:473-84; http://dx.doi.org/10.1016/0753-3322(92)90005-R
32. Wang W, Edington HD, Rao UN, Jukic DM, Radfar A, Wang H, et al. Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res 2008; 14:8314-20; http://dx.doi.org/10.1158/1078-0432.CCR-08-0705
33. Slingluff CL, Jr., Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 2011; 29:2924-32; http://dx.doi.org/10.1200/JCO.2010.33.8053
34. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151-60; http://dx.doi.org/10.1038/nrclinonc.2010. 223
35. Polak L, Turk JL. Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature 1974; 249:654-6; http://dx.doi.org/10.1038/249654a0
36. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005; 201:1591-602; http://dx.doi.org/10.1084/jem.20042167
37. Chen CA, Ho CM, Chang MC, Sun WZ, Chen YL, Chiang YC, et al. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther 2010; 18:1233-43; http://dx.doi.org/10.1038/mt.2010.34
38. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-8; http://dx.doi.org/10.1007/s00262-006-0225-8
39. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163:5211-8
40. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009; 1174:99-106; http://dx.doi.org/10.1111/j.1749-6632. 2009.04939.x
41. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008; 112:610-8; http://dx.doi.org/10.1182/blood-2008-01-135319
42. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206:1717-25; http://dx.doi.org/10.1084/jem.20082492
43. Coquerelle C, Oldenhove G, Acolty V, Denoeud J, Vansanten G, Verdebout JM, et al. Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis. Gut 2009; 58:1363-73; http://dx.doi.org/10.1136/gut.2008.162842
44. Ménard C, Ghiringhelli F, Roux S, Chaput N, Mateus C, Grohmann U, et al. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?. Clin Cancer Res 2008; 14:5242-9; http://dx.doi.org/10.1158/1078-0432.CCR-07-4797
45. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004; 200:771-82; http://dx.doi.org/10.1084/jem.20041130
46. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005; 202:885-91; http://dx.doi.org/10.1084/jem.20050940
47. Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 2004; 173:5008-20
48. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005; 105: 2845-51; http://dx.doi.org/10.1182/blood-2004-07-2959
49. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008; 205:825-39; http://dx.doi.org/10.1084/jem.20071341
50. Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, Lesokhin AM, et al. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 2009; 206:1103-16; http://dx.doi.org/10.1084/jem.20082205
51. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7:95-106; http://dx.doi.org/10.1038/nrc2051
52. Sutmuller RP, Morgan ME, Netea MG, Grauer O, Adema GJ. Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol 2006; 27:387-93; http://dx.doi.org/10. 1016/j.it.2006.06.005
53. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005; 309:1380-4; http://dx.doi.org/10.1126/science.1113401
54. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004; 5:508-15; http://dx.doi.org/10.1038/ni1059
55. Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010; 120:1285-97; http://dx.doi.org/10.1172/JCI36551
56. Conroy H, Marshall NA, Mills KH. TLR ligand suppression or enhancement of Treg cells? A doubleedged sword in immunity to tumours. Oncogene 2008; 27:168-80; http://dx.doi.org/10.1038/sj.onc.1210910
57. Blackburn MR, Vance CO, Morschl E, Wilson CN. Adenosine receptors and inflammation. Handb Exp Pharmacol 2009; 215-69; http://dx.doi.org/10.1007/978-3-540-89615-9_8
58. Michaud M, Martins I, Sukkurwala A, Adjemian S, Ma Y, Rello-Varona S, et al. Autophagy dictates anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; http://dx.doi.org/10.1126/science.1208347
59. Casares N, Rudilla F, Arribillaga L, Llopiz D, Riezu-Boj JI, Lozano T, et al. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol 2010; 185:5150-9; http://dx.doi.org/10.4049/jimmunol.1001114
60. Hirahara K, Liu L, Clark RA, Yamanaka K, Fuhlbrigge RC, Kupper TS. The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J Immunol 2006; 177:4488-94
61. Bayry J, Triebel F, Kaveri SV, Tough DF. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol 2007; 178:4184-93
62. Yuan Q, Bromley SK, Means TK, Jones KJ, Hayashi F, Bhan AK, et al. CCR4-dependent regulatory T cell function in inflammatory bowel disease. J Exp Med 2007; 204:1327-34; http://dx.doi.org/10.1084/jem.20062076
63. Bayry J, Tchilian EZ, Davies MN, Forbes EK, Draper SJ, Kaveri SV, et al. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci USA 2008; 105:10221-6; http://dx.doi.org/10.1073/pnas.0803453105
64. Davies MN, Bayry J, Tchilian EZ, Vani J, Shaila MS, Forbes EK, et al. Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors. PLoS ONE 2009; 4:e8084; http://dx.doi.org/10.1371/journal.pone.0008084
65. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007; 7:880-7; http://dx.doi.org/10.1038/nrc2250
66. Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 2009; 182:1746-55
67. Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, et al. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res 2010; 70:490-500; http://dx.doi.org/10.1158/0008-5472.CAN-09-1890
68. Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011; 30:83-95; http://dx.doi.org/10.1007/s10555-011-9281-4
69. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14:6674-82; http://dx.doi.org/10.1158/1078-0432.CCR-07-5212
70. Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33:991-8; http://dx.doi.org/10.1097/CJI.0b013e3181f4c208
71. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008; 111:5610-20; http://dx.doi.org/10.1182/blood-2007-02-075945
72. Desar IM, Jacobs JFM, Hulsbergen-vandeKaa CA, Oyen WJ, Mulders PF, van der Graaf WT, et al. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int J Cancer 2011; 129:507-12; http://dx.doi.org/10.1002/ijc.25674
73. Busse A, Asemissen AM, Nonnenmacher A, Braun F, Ochsenreither S, Stather D, et al. Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. Eur J Cancer 2011; 47:690-6; http://dx.doi.org/10.1016/j.ejca.2010.11.021
74. Belkaid Y, Oldenhove G. Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity 2008; 29:362-71; http://dx.doi.org/10.1016/j.immuni.2008.08.005
75. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5:2963-70
76. Suzuki H, Onishi H, Wada J, Yamasaki A, Tanaka H, Nakano K, et al. VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur J Immunol 2010; 40:197-203; http://dx.doi.org/10.1002/eji.200939887
77. Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 2011; 130:1948-59; http://dx.doi.org/10.1002/ijc.26219
78. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094-100; http://dx.doi.org/10.1038/nm.2438
79. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009; 58:1627-34; http://dx.doi.org/10.1007/s00262-009-0671-1
80. Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17:700-7; http://dx.doi.org/10.1038/nm.2366